| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CP12; P3-450; P450(PA) |
| WB Predicted band size | 58 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human CYP1A2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3-4条关于CYP1A2抗体的参考文献及其摘要：
1. **"Characterization of cytochrome P450 enzymes involved in drug metabolism using specific antibodies"**
*作者：Shimada T.等*
摘要：该研究利用特异性抗体分析CYP1A2等细胞色素P450酶在肝微粒体中的表达和活性，探讨其与药物代谢个体差异的关系。
2. **"Development and application of antibodies to human CYP1A2 in drug interaction studies"**
*作者：Butler M.A.等*
摘要：研究开发了针对人CYP1A2的单克隆抗体，用于评估咖啡因代谢及药物(如奥美拉唑)对酶活性的调控作用。
3. **"Role of CYP1A2 polymorphism in human metabolic phenotypes: Insights from antibody-based assays"**
*作者：Zhou S.F.等*
摘要：通过抗体免疫印迹技术，揭示CYP1A2基因多态性(如-164A>C)对酶表达水平的影响及其与药物毒性风险的关联。
4. **"CYP1A2-mediated drug interactions: Evidence from immunohistochemical and biochemical studies"**
*作者：Mikstacka R.等*
摘要：结合抗体标记技术，证明CYP1A2在肝癌组织中的异常表达及其与抗癌药物代谢的潜在相互作用。
注：以上内容为示例性文献，实际引用需以具体检索结果为准。
The CYP1A2 antibody is a crucial tool for studying the cytochrome P450 1A2 enzyme, a member of the cytochrome P450 superfamily involved in metabolizing xenobiotics and endogenous compounds. CYP1A2 is primarily expressed in the liver and plays a key role in the oxidation of numerous drugs (e.g., caffeine, clozapine) and procarcinogens (e.g., heterocyclic amines). This enzyme's activity is influenced by genetic polymorphisms, environmental factors (e.g., smoking), and drug interactions, impacting individual responses to therapeutics and disease risks.
CYP1A2 antibodies are widely used in research to detect enzyme expression, localization, and regulation via techniques like Western blotting, immunohistochemistry (IHC), and ELISA. They help investigate CYP1A2 induction by aryl hydrocarbon receptor (AhR) ligands (e.g., polycyclic aromatic hydrocarbons) or inhibition by compounds like fluvoxamine. Studies using these antibodies have linked altered CYP1A2 levels to conditions such as liver cancer, obesity, and metabolic disorders.
High-quality CYP1A2 antibodies are validated for specificity, often using knockout cell lines or tissues to confirm minimal cross-reactivity with related isoforms (e.g., CYP1A1). Their application advances understanding of drug metabolism, toxicity mechanisms, and personalized medicine strategies targeting CYP1A2 variability.
×
